Skip to content

LABORATORIA WOLFS

Active
Public limited companyfounded 1968active for 58 yearsWestpoort 50, 2070 Beveren-Kruibeke-Zwijndrecht, BelgiumKBO/BCE: BE 0404.812.870
Summary

LABORATORIA WOLFS has been active since 1968 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €2.5m and a net result of €841,339. Equity is growing by about 12% per year across the filed financial years. Its solvency ranks better than 37% of 88 sector peers (NACE 21, financial year 2025). The computed 12-month bankruptcy probability is 0.4% (very low).

Overview

Activity
Manufacture of basic pharmaceutical products and pharmaceutical preparations
NACE 21201
6th largest company by total assets in East Flanders, Pharmaceuticals sector1 site
Size
€12.2mturnover 2025
Staff
48.2 FTE
Equity
€2.5m
Profit
€841,339
Financial health
84 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
0.4%
Structure
Parent
OPDORP FINANCE · 89.19%
  • Adsum II BVDirector · permanent representative Pieter De Waele
  • Opdorp Finance BVDirector · permanent representative Annie Vereecken
Auditor: RSM INTERAUDITAccounts 32 days early2 of 18 deeds read
Why 84raises risk1 change of registered office in 24 monthsLiquidity: current ratio 1.59, cash €25,027lowers riskFounded in 1968Size: turnover €12.2m, 48.2 FTE, total assets €6.7mShow the evidence

Checked score

Score 2025
84 / 100
Excellent
Probability in this band: under 0.55%
Financially better than 51% of its sector peers (NACE 21, small)
Financial strength · tick = 2024
Strong
Solvency 61+11
equity 36.4% of total assets
Liquidity 38+5
short-term debt 29.7% · cash 0.4%
Profitability 81+15
return on assets 12.5%
Bankruptcy probability, 12 months
0.4% Very low
0%0.5%1.5%4%10%≥ 25%

About 4 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.5% (43 companies, NACE 21, small)
Last 24 months 11-2024: 0.7% 12-2024: 0.7%● unchanged vs 11-2024 01-2025: 0.7%● unchanged vs 12-2024 02-2025: 0.7%● unchanged vs 01-2025 03-2025: 0.7%● unchanged vs 02-2025 04-2025: 0.7%● unchanged vs 03-2025 05-2025: 0.7%● unchanged vs 04-2025 06-2025: 0.7%● unchanged vs 05-2025 07-2025: 0.4%▼ -0.3 percentage points vs 06-2025 08-2025: 0.4%● unchanged vs 07-2025 09-2025: 0.4%● unchanged vs 08-2025 10-2025: 0.4%● unchanged vs 09-2025 11-2025: 0.4%● unchanged vs 10-2025 12-2025: 0.4%● unchanged vs 11-2025 01-2026: 0.4%● unchanged vs 12-2025 02-2026: 0.7%▲ +0.3 percentage points vs 01-2026 03-2026: 0.7%● unchanged vs 02-2026 04-2026: 0.7%● unchanged vs 03-2026 05-2026: 0.9%▲ +0.2 percentage points vs 04-2026 06-2026: 0.9%● unchanged vs 05-2026highest value 07-2026: 0.4%▼ -0.5 percentage points vs 06-2026lowest value 08-2026: 0.4%● unchanged vs 07-2026lowest value 09-2026: 0.4%● unchanged vs 08-2026lowest value 10-2026: 0.4%● unchanged vs 09-2026lowest value
Credit of up to €200,000 on 30-day terms is acceptable
Liquidity ample (current ratio 1.59, compared with 1.24 in 2024, above the usual 1.5; short-term debt: 29.7% and cash: 0.4% of total assets), but 63.6% of the assets are financed with debt and provisions.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 21, small): better than 28% on solvency, 28% on liquidity, 74% on profitability and 75% on growth.

The bankruptcy probability was computed on 13-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Five signals.
lowers riskraises riskneutral
raises risk · 1 change of registered office in 24 months
Belgian Official Gazette
raises risk · Liquidity: current ratio 1.59, cash €25,027
NBB · annual accounts
lowers risk · Founded in 1968
Companies that have existed this long fail less often; how much that weighs depends on the rest of its profile.
KBO
lowers risk · Size: turnover €12.2m, 48.2 FTE, total assets €6.7m
Companies of this size fail less often; how much that weighs depends on the rest of its profile.
NBB · annual accounts
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 29-06-2026, 32 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
32 days early
2024
32 days early
2023
32 days early
2022
32 days early
2021
31 days early
2020
25 days early
2019
17 days late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 24 days before the deadline; the sector median (NACE 21) for financial year 2024 is 9 days before the deadline, and 32% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 29 June (5 of the last 5 filed years within 30 days of that day).
Companies Code · seven months
Where today falls in the filing period
13-10-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
Searched since 2021.
KBO publications · our coverage
  1. Resignations: Adsum II BV (director) and…Reappointments: Adsum II BV (director)…
  2. Annual accounts filedfinancial year 2025 · full…
  3. Appointment: RSM InterAudit (statutory auditor)Permanent representative: Kim Van Loon…

Key points

  • Positive: Result rose in 2025from €182,088 to €841,339 ▲ 362% View
  • Positive: 6th largest company by total assets in East Flanders, Pharmaceuticals sectorin the Checked rankings No. 6 View
  • Controlled by OPDORP FINANCE 89.19% View
  • New directorslatest change 19-06-2026 · 2 in office 2 joined View
  • Positive: Filed on time since financial year 2020accounts within the deadline every year 6 years View
  • Active since 1968founded 01-01-1968 58 years View

By topic

Financials

Financial year
2025
Turnover
€12.2m
Profit
€841,339
Solvency
36.4%
Turnover▲ 7.9%
Net result
20192025
Go to Financials

Board & ownership

Board
2 members
Parent
OPDORP FINANCE · 89.19%
Auditor
RSM INTERAUDIT
  • Adsum II BVDirector
  • Opdorp Finance BVDirector
Go to Board & ownership

Timeline

Events
57
Since
1978
Next accounts
by 31-07-2027
  1. 31-12-2025Highest result from 2018 to 2025
  2. 31-12-2025Equity above €2m
  3. 29-06-2025Annual accounts filed
Go to Timeline

Company details

Sites
1
Legal form
Public limited company
Activity
Manufacture of basic pharmaceutical products and pharmaceutical preparationsNACE 21201
Founded
01-01-1968
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Go further with this company

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.